Malignant Solid Tumor — A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours
Citation(s)
A Safety, Tolerability and Pharmacokinetic Dose Escalation and Expansion, Phase I/Ib Study of AMC303 as Monotherapy in Patients With Advanced or Metastatic, Malignant Solid Tumour of Epithelial Origin